102 results about "Early Gastric Cancer" patented technology

The invention discloses a compound fingerprint atlas model used in early-stage gastric cancer diagnosis / early warning, and an establishing method thereof. According to the invention, the concentration of a trace amount of volatile organic compound in a gastric cancer cell metabolic product is separated and detected by using a gas chromatograph-mass spectrometer, and the atlas model is drawn. A mass volume concentration ratio of 4-isopropoxy butanol to nonanal to 4-butoxyl n-butanol is represented by that: 4-isopropoxy butanol [gastric cancer cell] / [normal gastric mucosa cell] is no higher than 0.31, nonanal [gastric cancer cell] / [normal gastric mucosa cell] is no higher than 0.36, and 4-butoxyl n-butanol [gastric cancer cell] / [normal gastric mucosa cell] is no higher than 0.40. The gastric cancer cell metabolic product has characteristic peaks of 3-octanone and 2-butanone. Volatile organics in a cell metabolic product requiring detection are compared with the fingerprint atlas model provided by the invention, such that the fingerprint atlas model can be used in early-stage gastric cancer diagnosis and early warning.

The present invention relates to a novel use of the SDC2 (NM_002998, syndecan 2) gene as a biomarker of a gastric polyp and gastric cancer-specific methylation, and more particularly, to a use for diagnosing a gastric polyp and gastric cancer in an early stage by measuring the methylation level using the SDC2 gene as a biomarker. The present invention has the effect of providing a method which can provide information for the diagnosis of gastric cancer by detecting the methylation of a CpG island of a gastric polyp and a gastric cancer-specific marker gene. Also, using the method for detecting methylation and a composition, kit, and nucleic acid chip for diagnosis according to the present invention, gastric cancer can be diagnosed at an initial transformation stage, and thus, early diagnosis can be achieved. Therefore, the present invention is useful as it is possible to diagnose gastric cancer more accurately and rapidly than conventional methods.

A set of biomarkers indicative of early gastric cancer and method of diagnosing gastric cancer at an early stage by directing the these biomarkers in a blood sample. Detection of over-expression of one or more protein biomarks in the group consisting albumin, T-kininogen I, α-2-HS glycoprotein, α-1-antitrypsin, afamin and γ-actin and / or detection of under-expression of one or more protein biomarks in the group consisting stress 70 protein, apolipoprotein A-I, apolipoprotein A-IV, transthyretin and murinoglobulin is indicative of the presence of gastric cancer.

The invention discloses a gene marker for screening early gastric cancer. The gene marker comprises a peripheral blood gastric cancer characteristic gene sequence shown as SEQ ID NO.1-SEQ ID NO.6. The invention also discloses application of the gene marker in preparation of products for screening early gastric cancer. The gene marker disclosed by the invention is used for screening early gastric cancer and is high in sensitivity and specificity; and moreover, because the peripheral blood which can be easily collected in clinical application is taken as a detection sample, the detection is convenient, the gene marker is applicable to screening and early diagnosis of a large population for gastric cancer, and the application prospects are wide.

Disclosed herein are biomarkers related to gastric cancer. The presently identified salivary biomarkers create the basis for a gastric cancer detection bioassay with sensitivity and specificity. Means and methods for evaluating the data generated using multiple biomarkers in order to validate findings and further use of the multiplexed gastric cancer assay in clinical, diagnostic and therapeutic uses is also included.

The invention relates to a methylated biomarker or a combination thereof for detecting gastric cancer lymph node metastasis and non-metastasis and application of the methylated biomarker. The methylated biomarker is selected from at least one of chr12: 42873140, chr8: 81789921, chr8: 81811441 and chr8: 16884489. According to the invention, the appropriate DNA methylation biomarker is screened and used for detecting gastric cancer lymph node metastasis and non-metastasis, and the DNA methylation biomarker can achieve the purpose of accurate prediction. The novel DNA methylation marker developed by the invention can be used for identifying whether the lymph node metastasis of the early gastric cancer occurs or not, can be used for assisting clinical accurate diagnosis and guiding treatment, and also can be used for technical research in laboratories.

The invention discloses an auxiliary diagnosis system for early gastric cancer under an electronic staining endoscope based on deep learning, and the system comprises an image obtaining module which obtains a stomach image collected in real time in an examination process of the electronic staining endoscope; an early gastric cancer recognition module used for recognizing a focal zone and marking the focus area based on a pre-constructed early gastric cancer recognition model; and a logic judgment module used for judging whether the identified focal zone belongs to the same focal zone or not when the identified focal zone is overlapped. By means of a common electronic staining means, the invention provides the method for identifying the gastric early cancer based on an electronic staining endoscopic image, and the real-time performance, accuracy and practicability of detection are greatly improved.

The early stage stomach cancer detecting method with serum is to utilize fingerprint comprising ten proteins of charge / mass ratio 4141 Da, 4474 Da, 3940 Da, 4633 Da, 4792 Da, 3957 Da, 4976 Da, 5348 Da, 4096 Da and 5915 Da separately in detection. The detecting method includes the following specific steps: preparing serum, collecting mass spectrum data, and biological informatics analysis of the collected data. The present invention provides new concept and method for the early stage diagnosis of stomach cancer and lays foundation of new tumor marker. The method of the present invention is reasonable and feasible, and has combined biological informatics method and analysis method with specificity and sensitivity over 84 % each and greatly raised stomach cancer detecting rate.

The invention discloses a mass spectrum detection method of serum polypeptide. The method comprises the following steps: the magnetic bead supported matrix method is adopted to capture the gastric cancer peptidome in serum, a magnetic separator is used to separate magnetic beads and the sample without centrifuging the sample; and then the mass spectrum method is adopted to analyse the polypeptide spectrum. The method of the invention can be used to detect the serum samples of normal persons and patients with gastric cancer, and the detection result can be used as an important detection basis for the diagnosis of early gastric cancer. The detection method of the invention is accurate, convenient and fast.

The invention relates to a medicine for oral administration for treating carbuncle, gastritis, gastric ulcer and early gastric cancer. The medicine for oral administration comprises, by weight, from 1 to 2 parts of bamboo skin, from 0 to 2.5 parts of cortex lycii radicis, from 1.5 to 2.5 parts of Chinese honeylocust leaves, from 1 to 3 parts of dandelion, from 20 to 60 parts of soybeans and from 0.6 to 2 parts of edible calcined gypsum. The invention further provides a method for preparing the medicine for oral administration. The medicine for oral administration has effects of replenishing and activating blood, expelling noxious substances, diminishing inflammation, relieving swelling and pain, promoting blood circulation to remove blood stasis, eliminating necrotic tissues, promoting granulation, healing sore and the like, has the outstanding advantages of capability of becoming effective fast, short treatment course and obvious curative effect, can be taken conveniently, and is free of toxic and side effects, raw materials of the medicine are cheap and are good in compatibility, sources of the raw materials are abundant, and the preparation process is easy to control, popularize and apply.

The invention discloses traditional Chinese medicine for treating various diseases of the stomach. The traditional Chinese medicine is prepared from the following raw material medicine in parts by weight: 1 part of scorched hawthorn fruit, 1 part of rhizoma bletillae, 1 part of bighead atractylodes rhizome and 1 part of fructus aurantii immaturi. The scorched hawthorn fruit has the effects of improving digestion, strengthening stomach, activating blood circulation, eliminating stasis and relieving dysentery by astringency; the rhizoma bletillae has the effects of stopping bleeding by astringency, diminishing swelling and promoting tissue regeneration; the fructus aurantii immaturi has the effects of relieving stagnant Qi, removing retention, reducing phlegm and removing stasis; the bigheadatractylodes rhizome has the effects of invigorating spleen, supplementing qi and eliminating dampness to alleviate water retention; the four kinds of medicine are matched for jointly achieving the novel functions of removing necrotic tissues and promoting new tissue regeneration. A preparation method of the traditional Chinese medicine comprises the following steps of grinding the raw material medicine according to the weight parts into powder; performing uniform stirring; preparing the raw medicine into traditional Chinese medicine powder or granules; performing packaging according to a dose of 16g per bag. The four kinds of medicine are specially matched; the novel functions of removing necrotic tissues and promoting new tissue regeneration are achieved; various diseases in the stomachcan be effectively treated; the comprehensive effect is particularly good on chronic superficial gastritis, erosive gastritis, gastric ulcer, gastric polyps, early gastric cancer and intestinal metaplasia; the hypokinetic intestines and stomach function can be recovered; the treatment and health care functions are realized.